Uliledlimab is an antibody designed to target CD73. The development pause will also allow I-Mab to allow data from an ongoing ...

Antibodies that bind to a previously untargeted portion of the malaria parasite could lead to new monoclonal antibody treatments and vaccines for malaria.

Windward Bio has landed with a flurry of announcements, circling in a $200 million series A and offering up to $970 million ...

General Manager and CEO of Junshi Biosciences, Dr. Jianjun ZOU, said, “Toripalimab has made significant strides in its internationalization. As of today, toripalimab has been approved in 35 countries ...

A study published in Human Gene Therapy has involved the generation of a human monoclonal antibody (mAb) directed against ...

According to Inan’s team: “There is no documented production process of atezolizumab biosimilar in the literature except one ...

Dianthus Therapeutics is advancing treatments for autoimmune diseases. Read why DNTH stock is receiving Buy ratings and price ...